Pay attention to the outcome and the end point of anti-vascular endothelial growth factor therapy for retinopathy of prematurity

Yanrong Jiang

DOI: https://doi.org/10.3760/cma.j.issn.1005-1015.2019.02.002

2019-01-01

Abstract:In the expert consensus published by the Pediatrics in 2013,it was first proposed that anti-VEGF drugs can be considered for retinopathy ofprematurity (ROP) with stage 3,zone Ⅰ with plus disease.However,there are many problems worth the attention of ophthalmologists,including the advantages and disadvantages of anti-VEGF therapy compared with traditional laser therapy,systemic and ocular complications after anti-VEGF therapy,and what indicators are the end points of anti-VEGF therapy.Combined with this consensus and numerous research findings,we recommend that the first treatment for anti-VEGF or laser therapy should be considered from disease control effects.For the threshold and pre-threshold lesions,the effect of anti-VEGF therapy for zone Ⅱ lesions is better than that for zone Ⅰ lesions and the single-time effective rate is high.So,it is suggested that anti-VEGF therapy should be preferred for the first treatment.The choice of repeat treatment should be considered from the final retinal structure and functional prognosis.Laser therapy is advisable for the abnormal vascular regression slower and abnormalities in the posterior pole.It can reduce the number of reexaminations and prolong the interval between re-examinations.However,the premature use of laser has an inevitable effect on peripheral vision field.Excluding the above problems,supplemental therapy can still choose anti-VEGF therapy again.Most of the children with twice anti-VEGF therapy are sufficient to control the disease.Anti-VEGF therapy should be terminated when there are signs such as plus regression,threshold or pre-threshold lesions controlled without recurrence,peripheral vascularization,etc.